A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS ProtoKinetix, Incorporated (“ProtoKinetix,” “we,” “us,” “our,” or the “Company”) is a research and development stage bio-technology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins) or anti-aging glycoproteins, trademarked as AAGPs®. The Company has recently been in the process of directing major efforts to the practical side of commercial validation. The commercial applications for AAGPs® in large markets such as targeted health care solutions are numerous, and ProtoKinetix is currently working with researchers, business leaders and advisors and commercial entities to bring AAGP® to market. ProtoKinetix was incorporated as RJV Network, Inc. under the laws of the State of Nevada on December 23, 1999 for the primary purpose of developing an internet-based listing site that would provide detailed commercial real estate property listings and related data.
| Metric | TTM | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -376K | -168K | -449K | -197K | -1.2M | -1.4M |
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.02 |
| Free Cash Flow | 0 | -229K | -109K | -150K | -397K | -115K |
| ROIC | 0.0% | -1821.6% | -1353.3% | -233211.8% | -2433.2% | -1595.9% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.58 | -0.72 | -0.66 | -0.73 | -0.64 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 0 | -134K | -422K | -25M | -917K | -1.4M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -150.2% | - | - | - | - | - |
| Shares Outstanding | 392M | 198M | 198M | 170M | 123M | 69M |
| Metric | 2010 | 2011 | 2012 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 162K | 117K | 0 | 75K | 14K | 103K |
| SG&A | 213K | 201K | 119K | 96K | 142K | 63K |
| EBIT | -1.4M | -917K | -25M | -422K | -134K | 0 |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -1.4M | -1.2M | -197K | -449K | -168K | -376K |
| Net Margin | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | N/M | N/M | N/M | N/M | N/M | 0.0% |
| ROE | N/A | N/A | N/A | N/A | N/A | -150.2% |
| ROA | -2007.6% | -4138.0% | -2339.4% | -1820.2% | -1106.3% | -78.8% |
| Cash Flow | ||||||
| Op. Cash Flow | -115K | -397K | -150K | -105K | -229K | -181K |
| Free Cash Flow | -115K | -397K | -150K | -109K | -229K | 0 |
| Owner Earnings | -115K | -397K | -150K | -109K | -229K | -181K |
| CapEx | 0 | 0 | 0 | 3K | 0 | 0 |
| Maint. CapEx | 0 | 0 | 0 | 3K | 0 | 0 |
| Growth CapEx | N/A | N/A | N/A | 0 | N/A | 0 |
| D&A | 0 | 0 | 0 | 3K | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 72K | 37K | 23K | 81K | 20K | 20K |
| Balance Sheet | ||||||
| Net Debt | 271K | 328K | 330K | 438K | 247K | 0 |
| Cash & Equiv. | 14K | 5K | 2K | 3K | 0 | 0 |
| Long-Term Debt | N/A | N/A | N/A | N/A | 84K | 84K |
| Debt/Equity | -0.64 | -0.73 | -0.66 | -0.72 | -0.58 | 0.00 |
| Interest Coverage | -58.2 | -76.4 | -1036.4 | -16.0 | -3.9 | -3.9 |
| Equity | -468K | -460K | -507K | -618K | -428K | 250K |
| Total Assets | 69K | 30K | 8K | 25K | 6K | 478K |
| Total Liabilities | 538K | 490K | 516K | 643K | 434K | 227K |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 476K |
| Retained Earnings | N/A | N/A | N/A | -26M | -26M | -49M |
| Working Capital | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Assets | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Liabilities | 238K | 153K | 181K | 174K | 271K | 227K |
| Per Share Data | ||||||
| EPS | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Owner EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Book Value | -0.01 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 |
| Cash Flow/Share | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 69.4M | 123.2M | 170.4M | 198.0M | 198.0M | 391.6M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 6.9 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -2.9% | -16.1% | -8.8% | -1.4% | -2.4% | N/A |
| Market Cap | 4.0M | 2.5M | 1.7M | 7.9M | 9.5M | 1.7M |
| Avg. Price | 0.08 | 0.04 | 0.02 | 0.02 | 0.04 | 0.00 |
| Year-End Price | 0.06 | 0.02 | 0.01 | 0.04 | 0.05 | 0.00 |
ProtoKinetix, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
ProtoKinetix, Inc. (PKTX) has a market capitalization of $2M. It is classified as a small-cap stock.
ProtoKinetix, Inc. (PKTX) does not currently pay a regular dividend.
ProtoKinetix, Inc. (PKTX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
ProtoKinetix, Inc. (PKTX) generated $-229 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
The Ledger Terminal provides 5 years of financial data for ProtoKinetix, Inc. (PKTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
ProtoKinetix, Inc. (PKTX) has a book value per share of $-0.00, based on its most recent annual SEC filing.
No recent press releases.